Publications

Export 1384 results:
Sort by: Author Title [ Type  (Desc)] Year
Journal Article
Safaa, H. M., M. P. Serrano, D. G. Valencia, X. Arbe, R. Lazaro, and G. G. Mateos, "Effect on methionine, linoleic acid and addititional fat levels in diet and productivity and quality of Lohmann chickens in the final productive cycle", ITEA-INFORMACION TECNICA ECONOMICA AGRARIA, vol. 28, no. 1: ASOCIACION INTERPROFESIONAL DESARROLLO AGARIO, pp. 222–224, 2007. Abstract
n/a
Bielczyk, N. Z., A. Ando, A. P. Badhwar, C. Caldinelli, M. Gao, A. Haugg, L. M. Hernandez, K. L. Ito, D. Kessler, D. Lurie, et al., "Effective Self-Management for Early Career Researchers in the Natural and Life Sciences.", Neuron, vol. 106, issue 2, pp. 212-217, 2020. Abstract

Early career researchers (ECRs) are faced with a range of competing pressures in academia, making self-management key to building a successful career. The Organization for Human Brain Mapping undertook a group effort to gather helpful advice for ECRs in self-management.

Dawoud, D. M., M. Smyth, J. Ashe, T. Strong, D. Wonderling, J. Hill, M. Varia, P. Dyer, and J. Bion, "Effectiveness and cost effectiveness of pharmacist input at the ward level: a systematic review and meta-analysis.", Research in social & administrative pharmacy : RSAP, vol. 15, issue 10, pp. 1212-1222, 2019. Abstract

BACKGROUND: Pharmacists play important role in ensuring timely care delivery at the ward level. The optimal level of pharmacist input, however, is not clearly defined.

OBJECTIVE: To systematically review the evidence that assessed the outcomes of ward pharmacist input for people admitted with acute or emergent illness.

METHODS: The protocol and search strategies were developed with input from clinicians. Medline, EMBASE, Centre for Reviews and Dissemination, The Cochrane Library, NHS Economic Evaluations, Health Technology Assessment and Health Economic Evaluations databases were searched. Inclusion criteria specified the population as adults and young people (age >16 years) who are admitted to hospital with suspected or confirmed acute or emergent illness. Only randomised controlled trials (RCTs) published in English were eligible for inclusion in the effectiveness review. Economic studies were limited to full economic evaluations and comparative cost analysis. Included studies were quality-assessed. Data were extracted, summarised. and meta-analysed, where appropriate.

RESULTS: Eighteen RCTs and 7 economic studies were included. The RCTs were from USA (n = 3), Sweden (n = 2), Belgium (n = 2), China (n = 2), Australia (n = 2), Denmark (n = 2), Northern Ireland, Norway, Canada, UK and Netherlands. The economic studies were from UK (n = 2), Sweden (n = 2), Belgium and Netherlands. The results showed that regular pharmacist input was most cost effective. It reduced length-of-stay (mean = -1.74 days [95% CI: 2.76, -0.72], and increased patient and/or carer satisfaction (Relative Risk (RR) = 1.49 [1.09, 2.03] at discharge). At £20,000 per quality-adjusted life-year (QALY)-gained cost-effectiveness threshold, it was either cost-saving or cost-effective (Incremental Cost Effectiveness Ratio (ICER) = £632/QALY-gained). No evidence was found for 7-day pharmacist presence.

CONCLUSIONS: Pharmacist inclusion in the ward multidisciplinary team improves patient safety and satisfaction and is cost-effective when regularly provided throughout the ward stay. Research is needed to determine whether the provision of 7-day service is cost-effective.

Tarsia, M., A. Vitale, G. Ragab, and M. T. Hegazy, "Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry", Ophthalmology and Therapy, vol. Volume 13, pp. pages 761–774, 2024.
Esmat, G., T. Elbaz, M. E. Raziky, A. Gomaa, M. Abouelkhair, H. G. E. deen, A. Sabry, M. Ashour, N. Allam, M. Abdel-Hamid, et al., "Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis c genotype-4.", Journal of hepatology, 2017 Sep 18. Abstract

Although treatment of hepatitis C (HCV) and HCV-genotype-4 (GT4) has become very effective, yet treatment is very expensive, and affordable options are needed especially in limited resource countries.

OBJECTIVE: To assess the efficacy and safety of the combination of ravidasvir (an NS5A inhibitor) and sofosbuvir to treat chronic HCV-GT4 infected patients.

DESIGN: A total of three hundred patients with HCV-GT4 infection were recruited in 3 groups: treatment-naïve patients with or without compensated Child-A cirrhosis (Group 1); interferon-experienced patients without cirrhosis (Group 2); and interferon-experienced patients with cirrhosis (Group 3). Groups 1 and 2 received ravidasvir 200 mg QD plus sofosbuvir 400 mg QD for 12 weeks and were randomized 1:1 to treatment with or without weight-based ribavirin. Group 3 patients received ravidasvir plus sofosbuvir with ribavirin and were randomized 1:1 to a treatment duration of 12 weeks or 16 weeks. The primary endpoint was sustained virologic response at 12 weeks post treatment (SVR12).

RESULTS: Two-hundred ninety-eight patients were enrolled: 149 in Group 1, 79 in Group 2 and 70 in Group 3. SVR12 was achieved in 95.3% of all patients who started the study, including 98% of patients without cirrhosis and 91% of patients with cirrhosis, whether treatment-naïve or IFN-experienced. Ribavirin intake and history of previous interferon therapy did not affect SVR12 rates. No virologic breakthroughs were observed. Study treatment was well-tolerated.

CONCLUSIONS: Treatment with ravidasvir plus sofosbuvir, with or without ribavirin, was well-tolerated and associated with high sustained virologic response rate for HCV-GT4 infected patients with and without cirrhosis, regardless of previous interferon-based treatments.

Esmat, G., T. Elbaz, M. E. Raziky, A. Gomaa, M. Abouelkhair, H. G. E. deen, A. Sabry, M. Ashour, N. Allam, M. Abdel-Hamid, et al., "Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4.", Journal of hepatology, 2017 Sep 19. Abstract

BACKGROUND & AIMS: Although treatment of hepatitis C virus (HCV) and HCV-genotype-4 (GT4) has become very effective, it remains very expensive, and affordable options are needed, especially in limited resource countries. The aim of this study was to assess the efficacy and safety of the combination of ravidasvir (an NS5A inhibitor) and sofosbuvir to treat patients with chronic HCV-GT4 infection.

METHODS: A total of 300 patients with HCV-GT4 infection were recruited in three groups: treatment-naïve patients with or without compensated Child-A cirrhosis (Group 1); interferon-experienced patients without cirrhosis (Group 2); and interferon-experienced patients with cirrhosis (Group 3). Groups 1 and 2 received ravidasvir 200 mg QD plus sofosbuvir 400 mg QD for 12 weeks and were randomized 1:1 to treatment with or without weight-based ribavirin. Group 3 patients received ravidasvir plus sofosbuvir with ribavirin and were randomized 1:1 to a treatment duration of 12 weeks or 16 weeks. The primary endpoint was sustained virologic response at 12 weeks post-treatment (SVR12).

RESULTS: A total of 298 patients were enrolled: 149 in Group 1, 79 in Group 2 and 70 in Group 3. SVR12 was achieved in 95.3% of all patients who started the study, including 98% of patients without cirrhosis and 91% of patients with cirrhosis, whether treatment-naïve or interferon-experienced. Ribavirin intake and history of previous interferon therapy did not affect SVR12 rates. No virologic breakthroughs were observed and the study treatment was well tolerated.

CONCLUSIONS: Treatment with ravidasvir plus sofosbuvir, with or without ribavirin, was well tolerated and associated with high sustained virologic response rate for HCV-GT4 infected patients with and without cirrhosis, regardless of previous interferon-based treatments.

TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT02371408.

LAY SUMMARY: This study evaluated efficacy and safety of the new oral hepatitis C drug ravidasvir in combination with the approved oral drug sofosbuvir in 298 patients infected with hepatitis C type 4. Our results showed that treatment with ravidasvir plus sofosbuvir, with or without ribavirin, was well tolerated and associated with high response rate in patients with and without cirrhosis.

Aydinok, Y., A. Kattamis, D. M. Cappellini, A. El-Beshlawy, R. Origa, M. Elalfy, Y. Kilinç, S. Perrotta, Z. Karakas, V. Viprakasit, et al., "Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload.", Blood, vol. 125, issue 25, pp. 3868-77, 2015 Jun 18. Abstract

Deferasirox (DFX) monotherapy is effective for reducing myocardial and liver iron concentrations (LIC), although some patients may require intensive chelation for a limited duration. HYPERION, an open-label single-arm prospective phase 2 study, evaluated combination DFX-deferoxamine (DFO) in patients with severe transfusional myocardial siderosis (myocardial [m] T2* 5-<10 ms; left ventricular ejection fraction [LVEF] ≥56%) followed by optional switch to DFX monotherapy when achieving mT2* >10 ms. Mean dose was 30.5 mg/kg per day DFX and 36.3 mg/kg per day DFO on a 5-day regimen. Geometric mean mT2* ratios (Gmeanmonth12/24/Gmeanbaseline) were 1.09 and 1.30, respectively, increasing from 7.2 ms at baseline (n = 60) to 7.7 ms at 12 (n = 52) and 9.5 ms at 24 months (n = 36). Patients (17 of 60; 28.3%) achieved mT2* ≥10 ms and ≥10% increase from baseline at month 24; 15 switched to monotherapy during the study based on favorable mT2*. LIC decreased substantially from a baseline of 33.4 to 12.8 mg Fe/g dry weight at month 24 (-52%). LVEF remained stable with no new arrhythmias/cardiac failure. Five patients discontinued with mT2* <5 ms and 1 died (suspected central nervous system infection). Safety was consistent with established monotherapies. Results show clinically meaningful improvements in mT2* in about one-third of patients remaining on treatment at month 24, alongside rapid decreases in LIC in this heavily iron-overloaded, difficult-to-treat population. Combination therapy may be useful when rapid LIC reduction is required, regardless of myocardial iron overload. This trial was registered at www.clinicaltrials.gov as #NCT01254227.

Sonousi, A., V. A. Sarpe, M. Brilkova, J. Schacht, A. Vasella, E. C. Böttger, and D. Crich, "Effects of the 1-N-(4-Amino-2S-hydroxybutyryl) and 6′-N-(2-Hydroxyethyl) Substituents on Ribosomal Selectivity, Cochleotoxicity, and Antibacterial Activity in the Sisomicin Class of Aminoglycoside Antibiotics", ACS Infectious Diseases, vol. 4, issue 7: American Chemical Society, pp. 1114 - 1120, 2018. AbstractWebsite

n/a

Safaa, H. M., M. P. Serrano, D. G. Valencia, X. Arbe, E. Jiménez-Moreno, R. Lázaro, and G. G. Mateos, "Effects of the levels of methionine, linoleic acid, and added fat in the diet on productive performance and egg quality of brown laying hens in the late phase of production", Poultry science, vol. 87, no. 8: Oxford University Press, pp. 1595–1602, 2008. Abstract
n/a
Elmasry, S., S. Asfour, J. P. R. de Vaccari, and undefined, "Effects of Tobacco Smoking on the Degeneration of the Intervertebral Disc: A Finite Element Study", Plos One, 2015.
Khalifa, W., A. M. Samuel, F. H. SAMUEL, H. W. Doty, and S. VALTIERRA, "Effet des additions de bismuth et de calcium et du traitement thermique sur la microstructure et les propriétés mécaniques des alliages d'aluminium moulés B319", Fonderie, Fondeur d'aujourd'hui, issue 270, pp. 13-24, 2007.
Pennell, D. J., J. B. Porter, M. D. Cappellini, A. El-Beshlawy, L. L. Chan, Y. Aydinok, M. S. Elalfy, P. Sutcharitchan, C. - K. Li, H. Ibrahim, et al., "Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia.", Blood, vol. 115, issue 12, pp. 2364-71, 2010 Mar 25. Abstract

Cardiac iron overload causes most deaths in beta-thalassemia major. The efficacy of deferasirox in reducing or preventing cardiac iron overload was assessed in 192 patients with beta-thalassemia in a 1-year prospective, multicenter study. The cardiac iron reduction arm (n = 114) included patients with magnetic resonance myocardial T2* from 5 to 20 ms (indicating cardiac siderosis), left ventricular ejection fraction (LVEF) of 56% or more, serum ferritin more than 2500 ng/mL, liver iron concentration more than 10 mg Fe/g dry weight, and more than 50 transfused blood units. The prevention arm (n = 78) included otherwise eligible patients whose myocardial T2* was 20 ms or more. The primary end point was the change in myocardial T2* at 1 year. In the cardiac iron reduction arm, the mean deferasirox dose was 32.6 mg/kg per day. Myocardial T2* (geometric mean +/- coefficient of variation) improved from a baseline of 11.2 ms (+/- 40.5%) to 12.9 ms (+/- 49.5%) (+16%; P < .001). LVEF (mean +/- SD) was unchanged: 67.4 (+/- 5.7%) to 67.0 (+/- 6.0%) (-0.3%; P = .53). In the prevention arm, baseline myocardial T2* was unchanged from baseline of 32.0 ms (+/- 25.6%) to 32.5 ms (+/- 25.1%) (+2%; P = .57) and LVEF increased from baseline 67.7 (+/- 4.7%) to 69.6 (+/- 4.5%) (+1.8%; P < .001). This prospective study shows that deferasirox is effective in removing and preventing myocardial iron accumulation. This study is registered at http://clinicaltrials.gov as NCT00171821.

Shamaa, A., A. Mokbel, O. El- Tookhy, and A. Mostafa, "The efficiency of Intra-articular injection of amphotericin B in inducing arthritis in experimental Equine model", Vet. Med. , vol. 59, issue 3, no. 3, pp. 397–415, 2011. Abstract

n/a

Glasbey, J. C., D. Nepogodiev, J. F. F. Simoes, O. Omar, E. Li, M. L. Venn, PGDME, M. K. Abou Chaar, V. Capizzi, D. Chaudhry, et al., "Elective Cancer Surgery in COVID-19–Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study", Journal of Clinical Oncology, vol. 39, no. 1, pp. 66-78, 2021. AbstractWebsite

PURPOSEAs cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway.PATIENTS AND METHODSThis international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation).RESULTSOf 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76).CONCLUSIONWithin available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks.

Glasbey, J. C., T. E. F. Abbott, A. Ademuyiwa, A. Adisa, E. Alameer, S. Alshryda, A. P. Arnaud, B. Bankhead-Kendall, M. K. Abou Chaar, D. Chaudhry, et al., Elective surgery system strengthening: development, measurement, and validation of the surgical preparedness index across 1632 hospitals in 119 countries, , vol. 400, issue 10363, pp. 1607 - 1617, 2022. AbstractWebsite

SummaryBackground
The 2015 Lancet Commission on global surgery identified surgery and anaesthesia as indispensable parts of holistic health-care systems. However, COVID-19 exposed the fragility of planned surgical services around the world, which have also been neglected in pandemic recovery planning. This study aimed to develop and validate a novel index to support local elective surgical system strengthening and address growing backlogs.
Methods
First, we performed an international consultation through a four-stage consensus process to develop a multidomain index for hospital-level assessment (surgical preparedness index; SPI). Second, we measured surgical preparedness across a global network of hospitals in high-income countries (HICs), middle-income countries (MICs), and low-income countries (LICs) to explore the distribution of the SPI at national, subnational, and hospital levels. Finally, using COVID-19 as an example of an external system shock, we compared hospitals' SPI to their planned surgical volume ratio (SVR; ie, operations for which the decision for surgery was made before hospital admission), calculated as the ratio of the observed surgical volume over a 1-month assessment period between June 6 and Aug 5, 2021, against the expected surgical volume based on hospital administrative data from the same period in 2019 (ie, a pre-pandemic baseline). A linear mixed-effects regression model was used to determine the effect of increasing SPI score.
Findings
In the first phase, from a longlist of 103 candidate indicators, 23 were prioritised as core indicators of elective surgical system preparedness by 69 clinicians (23 [33%] women; 46 [67%] men; 41 from HICs, 22 from MICs, and six from LICs) from 32 countries. The multidomain SPI included 11 indicators on facilities and consumables, two on staffing, two on prioritisation, and eight on systems. Hospitals were scored from 23 (least prepared) to 115 points (most prepared). In the second phase, surgical preparedness was measured in 1632 hospitals by 4714 clinicians from 119 countries. 745 (45·6%) of 1632 hospitals were in MICs or LICs. The mean SPI score was 84·5 (95% CI 84·1–84·9), which varied between HIC (88·5 [89·0–88·0]), MIC (81·8 [82·5–81·1]), and LIC (66·8 [64·9–68·7]) settings. In the third phase, 1217 (74·6%) hospitals did not maintain their expected SVR during the COVID-19 pandemic, of which 625 (51·4%) were from HIC, 538 (44·2%) from MIC, and 54 (4·4%) from LIC settings. In the mixed-effects model, a 10-point increase in SPI corresponded to a 3·6% (95% CI 3·0–4·1; p<0·0001) increase in SVR. This was consistent in HIC (4·8% [4·1–5·5]; p<0·0001), MIC (2·8 [2·0–3·7]; p<0·0001), and LIC (3·8 [1·3–6·7%]; p<0·0001) settings.
Interpretation
The SPI contains 23 indicators that are globally applicable, relevant across different system stressors, vary at a subnational level, and are collectable by front-line teams. In the case study of COVID-19, a higher SPI was associated with an increased planned surgical volume ratio independent of country income status, COVID-19 burden, and hospital type. Hospitals should perform annual self-assessment of their surgical preparedness to identify areas that can be improved, create resilience in local surgical systems, and upscale capacity to address elective surgery backlogs.
Funding
National Institute for Health Research (NIHR) Global Health Research Unit on Global Surgery, NIHR Academy, Association of Coloproctology of Great Britain and Ireland, Bowel Research UK, British Association of Surgical Oncology, British Gynaecological Cancer Society, and Medtronic.

Gra, M. P. F., H. Fawzy, Y. Badr, M. M. Elokr, C. Nico, R. Soares, L. C. Costa, and M. A. Valente, "Electrical, Dielectric and Structural Properties of Borovanadate Glass Systems Doped With Samarium Oxide", phys status solidi C, 2011. Abstract

Glasses doped with rare earth (RE) ions are widely studied due to the numerous applications of these systems (active media for solid state lasers, optical telecommunication non-linear optical materials, electro-optic devices, etc.). Boron trioxide, B2O3, is a known glass forming oxide with a relative low melting temperature. The addition of a transition metal oxide, such as V2O5, promotes the exhibition of semiconducting properties making these promising systems for several technological applications, such that ones involved in solar energy conversion devices. It is known that alkali borovanadate glasses, like alkali borate glasses themselves, are ionically conducting materials. Despite their importance there are only few studies on these glasses reported on literature. Thus, the alkali-borovanadate glass system constitutes a family with high interest from the electrical and dielectric point of view. The effect of the increment of alkali quantity in the electrical and dielectric response of these glasses and the physical/structural explanation are questions which will be addressed. In this work, the transparent glass samples with molar composition 0.01Sm2O3- 0.99[0.85B2O3-(0.15-x)Li2O-xV2O5] with x = 0, 0.1, 0.2, 0.35, 0.5 and 2 (mol %) were prepared by conventional melting technique. The prepared samples were fullycharacterized using different experimental techniques such as, differential thermal analysis (DTA), X-ray diffraction (XRD), electrical and dielectric measurements. The samples structure, electrical and dielectric properties as a function of vanadium ions content was explored and discussed.

Graça, M. P. F., H. Fawzy, Y. Badr, M. M. Elokr, C. Nico, R. Soares, L. C. Costa, and M. A. Valente, "Electrical, dielectric and structural properties of borovanadate glass systems doped with samarium oxide", Physica Status Solidi (C) Current Topics in Solid State Physics, vol. 8, no. 11-12, pp. 3107-3110, 2011. AbstractWebsite
n/a
Graça, M. P. F., H. Fawzy, Y. Badr, M. M. Elokr, C. Nico, R. Soares, L. C. Costa, and M. A. Valente, "Electrical, dielectric and structural properties of borovanadate glass systems doped with samarium oxide", physica status solidi (c), 2011.
Lederer, C. W., N. A. Basak, Y. Aydinok, S. Christou, A. El-Beshlawy, A. Eleftheriou, S. Fattoum, A. E. Felice, E. Fibach, R. Galanello, et al., "An electronic infrastructure for research and treatment of the thalassemias and other hemoglobinopathies: the Euro-mediterranean ITHANET project.", Hemoglobin, vol. 33, issue 3, pp. 163-76, 2009. Abstract

Hemoglobin (Hb) disorders are common, potentially lethal monogenic diseases, posing a global health challenge. With worldwide migration and intermixing of carriers, demanding flexible health planning and patient care, hemoglobinopathies may serve as a paradigm for the use of electronic infrastructure tools in the collection of data, the dissemination of knowledge, the harmonization of treatment, and the coordination of research and preventive programs. ITHANET, a network covering thalassemias and other hemoglobinopathies, comprises 26 organizations from 16 countries, including non-European countries of origin for these diseases (Egypt, Israel, Lebanon, Tunisia and Turkey). Using electronic infrastructure tools, ITHANET aims to strengthen cross-border communication and data transfer, cooperative research and treatment of thalassemia, and to improve support and information of those affected by hemoglobinopathies. Moreover, the consortium has established the ITHANET Portal, a novel web-based instrument for the dissemination of information on hemoglobinopathies to researchers, clinicians and patients. The ITHANET Portal is a growing public resource, providing forums for discussion and research coordination, and giving access to courses and databases organized by ITHANET partners. Already a popular repository for diagnostic protocols and news related to hemoglobinopathies, the ITHANET Portal also provides a searchable, extendable database of thalassemia mutations and associated background information. The experience of ITHANET is exemplary for a consortium bringing together disparate organizations from heterogeneous partner countries to face a common health challenge. The ITHANET Portal as a web-based tool born out of this experience amends some of the problems encountered and facilitates education and international exchange of data and expertise for hemoglobinopathies.

Mostafa, H. I. A., G. Varo, R. Toth-Boconadi, A. Der, and L. Keszthelyi, "Electrooptical measurements on purple membrane containing bacteriorhodopsin mutants", Biophysical Journal, vol. 70, no. 1, pp. 468-472, 1996. Abstract
n/a
Vogel, C. V., H. Pietraszkiewicz, O. M. Sabry, W. H. Gerwick, F. A. Valeriote, and C. D. Vanderwal, "Enantioselective divergent syntheses of several polyhalogenated Plocamium monoterpenes and evaluation of their selectivity for solid tumors.", Angewandte Chemie (International ed. in English), vol. 53, issue 45, pp. 12205-9, 2014 Nov 3. Abstract

The family of polyhalogenated monoterpenes from Plocamium counts over a hundred known members. Using glyceraldehyde acetonide as a chiral-pool precursor, an enantioselective and divergent strategy was developed that provides a blueprint for the synthesis of many of the small yet complex acyclic members of this family. The broad applicability of this approach is demonstrated with the short, eight-step synthesis of four natural products and three analogues. These syntheses are the first of any members of the acyclic polyhalogenated Plocamium monoterpenes and permitted the evaluation of their selectivity against a range of tumor cell lines.

VOGEL, C. V., H. PIETRASZKIEWICZ, S. A. B. R. Y. M. OMAR, W. H. GERWICK, F. A. VALERIOTE, and C. D. VANDERWAL, "Enantioselective, Divergent Syntheses of Several Polyhalogenated Plocamium Monoterpenes and Evaluation of their Selectivity for Solid Tumors", Angewandte Chem. Int. Ed. , vol. 53, issue 45, pp. 12205–12209, 2014. plocamium_monoterpenes.pdf
Davino, D., A. Giustiniani, C. Visone, and A. A. Adly, "Energy harvesting tests with Galfenol at variable magneto-mechanical conditions", Magnetics, IEEE Transactions on, vol. 48, no. 11: IEEE, pp. 3096–3099, 2012. Abstract
n/a
Davino, D., A. Giustiniani, C. Visone, and A. A. Adly, "Energy harvesting tests with Galfenol at variable magneto-mechanical conditions", Magnetics, IEEE Transactions on, vol. 48, no. 11: IEEE, pp. 3096–3099, 2012. Abstract
n/a
Tourism